Mauricio Burotto
Universidad de Los Andes, Chile(CL)Finis Terrae University(CL)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Economic and Financial Impacts of Cancer
Most-Cited Works
- → Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2021)1,675 cited
- → The MAPK pathway across different malignancies: A new perspective(2014)970 cited
- → Pseudoprogression and Immune-Related Response in Solid Tumors(2015)891 cited
- → Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial(2020)517 cited
- → Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma(2023)431 cited
- → The Strength of Association Between Surrogate End Points and Survival in Oncology(2015)376 cited
- → Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial(2022)291 cited
- → Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma(2022)259 cited
- → Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins(2015)180 cited
- → Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial(2024)157 cited